Xeris Biopharma Holdings, Inc. NASDAQ:XERS

Xeris Biopharma Holdings stock price today

$7.321
+3.89
+113.45%
Financial Health
0
1
2
3
4
5
6
7
8
9

Xeris Biopharma Holdings stock price monthly change

+45.34%
month

Xeris Biopharma Holdings stock price quarterly change

+45.34%
quarter

Xeris Biopharma Holdings stock price yearly change

+50.77%
year

Xeris Biopharma Holdings key metrics

Market Cap
501.65M
Enterprise value
357.58M
P/E
-2.84
EV/Sales
3.24
EV/EBITDA
-5.10
Price/Sales
2.55
Price/Book
6.22
PEG ratio
-0.05
EPS
-0.59
Revenue
137.14M
EBITDA
-50.52M
Income
-81.84M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
-85.86%
Oper. margin
-74.32%
Gross margin
79.47%
EBIT margin
-74.32%
EBITDA margin
-36.84%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Xeris Biopharma Holdings stock price history

Xeris Biopharma Holdings stock forecast

Xeris Biopharma Holdings financial statements

Average Price Target
Last Year

$5.8

Potential downside: -20.77%

Based on estimate of 2 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS): Profit margin
Jun 2022 25.30M -26.18M -103.47%
Mar 2023 33.19M -16.83M -50.71%
Jun 2023 38.00M -19.84M -52.2%
Mar 2024 40.63M -18.98M -46.71%
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS): Earnings per share (EPS)
2022-11-09 -0.16 -0.16
2023-03-08 -0.06349 -0.1
2023-05-09 -0.08572 -0.12
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS): Debt to assets
Dec 2022 328778000 315.13M 95.85%
Mar 2023 321360000 291.31M 90.65%
Jun 2023 328778000 315.13M 95.85%
Mar 2024 336616000 345.79M 102.73%
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS): Cash Flow
Jun 2022 -20.60M 11.86M 310K
Mar 2023 -26.14M -43.97M -863K
Jun 2023 -13.74M 8.45M 556K
Mar 2024 -20.30M -19.65M 35.19M

Xeris Biopharma Holdings alternative data

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS): Employee count
Aug 2023 355
Sep 2023 355
Oct 2023 355
Nov 2023 355
Dec 2023 355
Jan 2024 355
Feb 2024 355
Mar 2024 377
Apr 2024 377
May 2024 377
Jun 2024 377
Jul 2024 377

Xeris Biopharma Holdings other data

63.87% +2.18%
of XERS is owned by hedge funds
50.47M +9.45M
shares is hold by hedge funds

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS): Insider trades (number of shares)
Period Buy Sel
Nov 2023 82449 0
May 2024 5400 0
Aug 2024 8800 0
Transaction Date Insider Security Shares Price per share Total value Source
Option
PIEPER STEVEN officer: See Remarks
Common Stock 19,483 $1.55 $30,199
Option
PIEPER STEVEN officer: See Remarks
Stock Option (Right to Buy) 2,640 $1.55 $4,092
Purchase
SCHMID JOHN P. director
Common Stock 4,515 $2.25 $10,145
Purchase
SCHMID JOHN P. director
Common Stock 4,285 $2.37 $10,134
Purchase
SCHMID JOHN P. director
Common Stock 5,400 $1.91 $10,314
Option
JOHNSON JOHN director
Common Stock 215,600 $1.99 $429,044
Option
JOHNSON JOHN director
Stock Option (Right to Buy) 215,600 $1.99 $429,044
Purchase
SHERMAN JEFFREY W director
Common Stock 5,400 $1.87 $10,098
Purchase
HALKUFF DAWN director
Common Stock 5,410 $1.84 $9,954
Purchase
PIEPER STEVEN officer: See Remarks
Common Stock 28,000 $1.95 $54,600
Patent
Grant
Filling date: 31 Jul 2020 Issue date: 20 Sep 2022
Application
Filling date: 13 May 2021 Issue date: 31 Mar 2022
Application
Filling date: 25 Jun 2021 Issue date: 30 Dec 2021
Application
Filling date: 29 Mar 2021 Issue date: 14 Oct 2021
Grant
Filling date: 6 Aug 2015 Issue date: 28 Sep 2021
Grant
Filling date: 31 May 2018 Issue date: 1 Jun 2021
Grant
Filling date: 22 Mar 2016 Issue date: 27 Apr 2021
Application
Filling date: 23 Jan 2019 Issue date: 4 Feb 2021
Application
Filling date: 21 Dec 2018 Issue date: 14 Jan 2021
Application
Filling date: 29 May 2020 Issue date: 3 Dec 2020
Tuesday, 26 November 2024
businesswire.com
Friday, 8 November 2024
seekingalpha.com
zacks.com
zacks.com
businesswire.com
Thursday, 31 October 2024
businesswire.com
Friday, 25 October 2024
seekingalpha.com
Friday, 11 October 2024
seekingalpha.com
Wednesday, 9 October 2024
seekingalpha.com
Friday, 4 October 2024
businesswire.com
Friday, 30 August 2024
247wallst.com
Thursday, 8 August 2024
seekingalpha.com
zacks.com
Thursday, 1 August 2024
zacks.com
Wednesday, 24 July 2024
zacks.com
Monday, 8 July 2024
proactiveinvestors.com
Wednesday, 3 July 2024
businesswire.com
Monday, 3 June 2024
businesswire.com
Thursday, 30 May 2024
businesswire.com
businesswire.com
Thursday, 9 May 2024
Proactive Investors
Zacks Investment Research
Monday, 6 May 2024
Proactive Investors
Saturday, 30 March 2024
Seeking Alpha
Wednesday, 6 March 2024
Proactive Investors
Zacks Investment Research
Tuesday, 5 March 2024
Zacks Investment Research
Monday, 5 February 2024
Business Wire
Thursday, 11 January 2024
Zacks Investment Research
Wednesday, 10 January 2024
Proactive Investors
  • What's the price of Xeris Biopharma Holdings stock today?

    One share of Xeris Biopharma Holdings stock can currently be purchased for approximately $7.32.

  • When is Xeris Biopharma Holdings's next earnings date?

    Unfortunately, Xeris Biopharma Holdings's (XERS) next earnings date is currently unknown.

  • Does Xeris Biopharma Holdings pay dividends?

    No, Xeris Biopharma Holdings does not pay dividends.

  • How much money does Xeris Biopharma Holdings make?

    Xeris Biopharma Holdings has a market capitalization of 501.65M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 447% to 110.25M US dollars. Xeris Biopharma Holdings made a loss 94.66M US dollars in net income (profit) last year or -$0.12 on an earnings per share basis.

  • What is Xeris Biopharma Holdings's stock symbol?

    Xeris Biopharma Holdings, Inc. is traded on the NASDAQ under the ticker symbol "XERS".

  • What is Xeris Biopharma Holdings's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Xeris Biopharma Holdings?

    Shares of Xeris Biopharma Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Xeris Biopharma Holdings's key executives?

    Xeris Biopharma Holdings's management team includes the following people:

    • Mr. Paul R. Edick Chairman & Chief Executive Officer(age: 69, pay: $1,090,000)
    • Mr. John P. Shannon Pres, Chief Operating Officer & Director(age: 63, pay: $776,080)
    • Ms. Beth P. Hecht J.D. Senior Vice President, Gen. Counsel, Corporation Sec. & Director(age: 61, pay: $588,290)
  • How many employees does Xeris Biopharma Holdings have?

    As Jul 2024, Xeris Biopharma Holdings employs 377 workers.

  • When Xeris Biopharma Holdings went public?

    Xeris Biopharma Holdings, Inc. is publicly traded company for more then 7 years since IPO on 21 Jun 2018.

  • What is Xeris Biopharma Holdings's official website?

    The official website for Xeris Biopharma Holdings is xerispharma.com.

  • Where are Xeris Biopharma Holdings's headquarters?

    Xeris Biopharma Holdings is headquartered at 180 North LaSalle Street, Chicago, IL.

  • How can i contact Xeris Biopharma Holdings?

    Xeris Biopharma Holdings's mailing address is 180 North LaSalle Street, Chicago, IL and company can be reached via phone at +84 44455704.

  • What is Xeris Biopharma Holdings stock forecast & price target?

    Based on 2 Wall Street analysts` predicted price targets for Xeris Biopharma Holdings in the last 12 months, the avarage price target is $5.8. The average price target represents a -20.77% change from the last price of $7.32.

Xeris Biopharma Holdings company profile:

Xeris Biopharma Holdings, Inc.

xerispharma.com
Exchange:

NASDAQ

Full time employees:

377

Industry:

Biotechnology

Sector:

Healthcare

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

180 North LaSalle Street
Chicago, IL 60601

CIK: 0001867096
ISIN: US98422E1038
CUSIP: 98422E103